Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ANI Pharma acquires Lithobid tablets from Noven Therapeutics
The company said that total consideration for the product was $12m including an $11m upfront payment and a $1m future milestone payment. ANI intends to launch Lithobid under
The company said that total consideration for the product was $12m including an $11m upfront payment and a $1m future milestone payment. ANI intends to launch Lithobid under
The acquisition will allow Encore leverage Quintiles’ breadth and depth of capabilities as well as its global scale to speed up Encore’s vision of improving clinical outcomes through
The company secured a sublicense agreement to manufacture, market and distribute the oral spray product under the brand name TapouT XT in 2013 and since such time has
In 2011, both the firms signed a collaboration and license option agreement for several pre-defined pathogens. As part of the 2011 deal, CureVac met all pre-agreed milestones and
Lemtrada, a monoclonal antibody that selectively targets CD52, has been approved by ANMAT to treat adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by
So far, WILEX has completed many clinical studies with Mesupron in different indications, including two Phase II proof of concept trials for pancreatic cancer and metastatic breast cancer.
Eisai’s E6201 is a dual-targeted FLT3 and MEK inhibitor, which has completed a PhaseI clinical trial showing preliminary antitumor activity and an acceptable safety profile. Building on a
The deal grants Merz an exclusive North American license, with certain additional international rights, for the development and commercialization of BBI-3000, to treat skin conditions known to be
Under the deal, AcipHex Sprinkle will be distributed by FSC Laboratories and promoted by its subsidiary, FSC Pediatrics, to pediatric primary care-focused practitioners across the US. FSC Pediatrics
The company is focused on using its Verisome drug-delivery platform in the development of new unique intraocular eye-care therapeutics. IBI-10090, which employs the Verisome technology, has been designed